Clinical trials: Calciphylaxis
Calciphylaxis, Calcific Uremic Arteriolopathy
Phase 3 Study of SNF472 for Calciphylaxis
The primary objectives are to assess the efficacy, safety, and tolerability of SNF472 compared to placebo when added to background care for the treatment of calciphylaxis (CUA).
- Trial name
- Calciphyx (NCT04195906)
- Testing
- Experimental: SNF472, Experimatenl SNF472 (Open-label)
- Where
- 58 sites in United States, Belgium and 4 more
- Volunteers
- 71 people
- Sponsor
- Sanifit Therapeutics S. A.
Calciphylaxis
Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome
Calciphylaxis, also called Calcific Uremic Arteriolopathy (CUA) is a lethal affection mostly affecting patient in end stage renal disease. The survival rate is described around 20 to 46% at one year.
- Trial name
- CalciWest (NCT02854046)
- Testing
- Calcific Uremic Arteriolopathy
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Nantes University Hospital
Calciphylaxis
Anti-Interleukin-6 (IL6) in Calciphylaxis
Calciphylaxis is a rare but incredibly dangerous condition that causes small blood vessels in the skin to become blocked by calcium buildup and blood clots. This leads to painful skin sores (necrosis) that do not heal easily.
- Trial name
- NCT07708038
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Boston Medical Center
Diabetic Foot, Pressure Ulcer
A Real-World Registry of Chronic Wounds and Ulcers
WOUNDJOURNEY is a longitudinal, real-world, observational registry designed to capture the full clinical course and patient journey associated with chronic wounds and ulcers.
- Conditions
- Diabetic Foot, Pressure Ulcer, Surgical Wound Dehiscence, Vasculitis
- Trial name
- WOUNDJOURNEY (NCT02280733)
- Testing
- Usual care
- Where
- United States
- Volunteers
- 300,000 people
- Sponsor
- U.S. Wound Registry
Calciphylaxis, Renal Insufficiency, Chronic
The Early Administration of Sodium Thiosulfate Should Help to Reduce the Mortality of Dialysis Patients With Calciphylaxis, From a National Cohort
The national drug safety agency authorizes nominatively the use of sodium thiosulfate in dialysis patients with calciphylaxis. To date, it is the largest global cohort (more 600 patients from 2012 to 2016).
- Trial name
- NCT03146793
- Testing
- Sodium Thiosulfate
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier St Esprit
Calciphylaxis, Calcific Uremic Arteriolopathy
Partners Calciphylaxis Biobank
Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles.
- Conditions
- Calciphylaxis, Calcific Uremic Arteriolopathy, End Stage Renal Disease, Chronic Kidney Diseases
- Trial name
- PCB (NCT03032835)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Massachusetts General Hospital
Calciphylaxis
Study of EPN-701 for the Treatment of Calciphylaxis
Calciphylaxis is a rare but serious condition that leads to painful skin lesions. At present, there is no approved treatment for calciphylaxis.
- Trial name
- NCT07583745
- Testing
- EPN-701 (Oral)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sagar U. Nigwekar, MD, MMSc
Calciphylaxis, Calcific Uremic Arteriolopathy
Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy
Calcific uremic arteriolopathy a.k.a. calciphylaxis is a vascular calcification disorder seen in dialysis patients. Calcific uremic arteriolopathy has 60-80% one-year mortality and significant morbidity associated with…
- Trial name
- VitK-CUA (NCT02278692)
- Testing
- Vitamin K
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Massachusetts General Hospital
Chronic Kidney Diseases, Calciphylaxis
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
- Conditions
- Chronic Kidney Diseases, Calciphylaxis, Calcific Uremic Arteriolopathy, Treatment
- Trial name
- NCT04592640
- Testing
- Human amniotic-derived mesenchymal stem cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Calciphylaxis, Calcific Uremic Arteriolopathy
Calciphylaxis in Patients With Chronic Kidney Disease - A Study of the Danish Calciphylaxis Research Initiative (DanCaRI)
Calciphylaxis is a rare yet life-threatening condition involving pronounced calcification in small blood vessels of the skin. Knowledge about its underlying mechanisms and contributing risk factors remains limited.
- Conditions
- Calciphylaxis, Calcific Uremic Arteriolopathy, End Stage Renal Disease (ESRD), Chronic Kidney Diseases
- Trial name
- NCT07511283
- Where
- Denmark
- Volunteers
- 860 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Calciphylaxis
Efficacy of Lanthanum Carbonate in Calciphylaxis
The research question and primary aim is to determine if lanthanum carbonate is effective in treating calciphylaxis by measurement of complete or partial remission of skin lesions.
- Trial name
- NCT01289626
- Testing
- lanthanum carbonate, Lanthanum for calciphylaxis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Hypertensive Ischemic Leg Ulcer, Calciphylaxis
Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU)
Martorell hypertensive ischemic leg ulcer is a severe type of skin necrosis (skin infarction) which occurs in long-term hypertensive subjects.
- Trial name
- NCT01578382
- Where
- Switzerland
- Volunteers
- 120 people
- Sponsor
- University of Zurich
Calciphylaxis
Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate
This is an 8-week observational follow-up study of patients who participated in the ST-001 CALISTA study (A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind…
- Trial name
- OF-CALISTA (NCT03319914)
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Hope Pharmaceuticals
Calciphylaxis
Better Evidence and Translation for Calciphylaxis
This global platform study will evaluate multiple interventions, across several domains of therapeutic care, in adult patients with kidney failure and newly diagnosed calciphylaxis.
- Trial name
- BEAT-Calci (NCT05018221)
- Testing
- Vitamin K1, Magnesium citrate, Sodium Thiosulfate
- Where
- 21 sites in Australia, New Zealand
- Volunteers
- 350 people
- Sponsor
- University of Sydney
Rheopheresis, Calcifying Uremic Arteriolopathy
Retrospective Study Evaluating the Contribution of Rheopheresis in the Treatment of Uremic Calciphylaxis (RHEO-CUA)
Calcifying uremic arteriolopathy (or uremic calciphylaxis) is a rare disease (prevalence <1% of dialysis patients), but the prognosis is often catastrophic.
- Conditions
- Rheopheresis, Calcifying Uremic Arteriolopathy, Uremic Calciphylaxis
- Trial name
- RHEO-CUA (NCT05633121)
- Testing
- Rheopheresis
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Association ECHO
Metabolic Disorder, End Stage Renal Disease
Rheopheresis as Adjuvant Treatment of Calciphylaxis
The investigators propose to set up a prospective randomized controlled trial to control the security and assess the efficacy of adjuvant treatment by rheopheresis in necrotizing-ulcered calciphylaxis in the hemodialysis…
- Conditions
- Metabolic Disorder, End Stage Renal Disease, Rare Diseases
- Trial name
- RHEO-CAL (NCT04654000)
- Testing
- Rheopheresis procedure
- Where
- 29 sites in France
- Volunteers
- 138 people
- Sponsor
- University Hospital, Lille
Calciphylaxis
SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney Disease
This Phase 1, open-label, multicenter study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INZ-701 in adults with hemodialysis-dependent end-stage kidney disease (ESKD) and low plasma inorganic…
- Trial name
- SEAPORT 1 (NCT06283589)
- Testing
- INZ-701
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Inozyme Pharma
Calciphylaxis, Calcific Uremic Arteriolopathy
Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy
To evaluate the efficacy of Sodium Thiosulfate (STS) compared to placebo, in reducing analgesic requirement in subjects with calcific uremic arteriolopathy (CUA) during an initial 28-day treatment phase.
- Trial name
- NCT02527213
- Testing
- Sodium thiosulfate
- Where
- 3 sites in United States
- Sponsor
- American Regent, Inc.
Calciphylaxis, Calcific Uremic Arteriolopathy
Phase 2 Study With SNF472 in Calciphylaxis Patients
To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).
- Trial name
- NCT02790073
- Testing
- SNF472
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 14 people
- Sponsor
- Sanifit Therapeutics S. A.